177Lu-Radiopharmaceutical
177Lu radiopharmaceuticals employ 177Lu isotopes for targeted cancer therapies, frequently used in advanced oncology treatments and innovative radio immunotherapies. Alfa Cytology offers expert 177Lu radiopharmaceutical development services, providing comprehensive and tailored technical support from radiolabel synthesis to detailed preclinical studies and trials.
Overview of 177Lu-Radiopharmaceutical
177Lu-Radiopharmaceuticals are a class of radiopharmaceuticals that utilize the isotope 177Lutetium (177Lu), widely employed in oncology treatments, particularly in targeted therapies. 177Lu is a beta-emitting radioisotope with a moderate half-life of approximately 6.7 days and excellent radiological properties. It effectively releases beta particles for cellular destruction and uses gamma rays for visual image tracking, making it ideal for targeted radiotherapy and image-guided therapy.
![Chemical structure of [177Lu] Lu-PSMA-617.](https://www.rdcthera.com/wp-content/themes/rdc/upload/2-1-1-1-10-177lu-radiopharmaceutical-1.jpg)
Fig 1. Chemical structure of [177Lu] Lu-PSMA-617. (HENNRICH U, et al., 2022)
Our Services
Alfa Cytology possesses leading scientific research capabilities, specializing in the development and preclinical research of 177Lu radiopharmaceuticals. The company is dedicated to providing innovative solutions for targeted cancer therapy. With an advanced technology platform, Alfa Cytology facilitates the efficient development and precise application of 177Lu radiopharmaceuticals.
Small Molecule Drugs
Small molecule drugs target specific cellular markers or pathways and can efficiently penetrate tumor tissues once labeled with 177Lu. This labeling enhances their ability to deliver targeted treatment.
Monoclonal Antibodies (mAbs)
These antibodies specifically bind to antigens on tumor cells. When labeled with 177Lu, they deliver targeted radiation to the tumor, improving treatment precision. A notable example is 177Lu-Dotatate, which targets neuroendocrine tumors.
Peptides
Peptide molecules can target specific receptors on certain tumor cells when bound to 177Lu. Compared to monoclonal antibodies, peptides have smaller molecular weights, allowing them to penetrate tumor tissues more easily and achieve rapid therapeutic effects.
Immunoconjugates
Immunoconjugates are drugs that combine antibodies with radioisotopes, drugs, toxins, or other agents through chemical linkages. Using 177Lu as a radiolabel allows for the precise delivery of antibodies or other targeting molecules to the tumor site, enhancing therapeutic precision.
177Lu-Radiopharmaceutical Development
Target Identification: Select specific receptors or antigens for 177Lu radiopharmaceutical development.
Targeting Molecules: Choose molecules like monoclonal antibodies or peptides for precise tumor targeting.
Radioisotope Labeling: Combine 177Lu with target molecules, ensuring stability and biological activity.
Optimization: Enhancing the labeling method can improve the radiopharmaceutical's efficiency and stability.
Evaluation: Test 177Lu-labeled drugs for target binding, cellular uptake, and release.
Cytotoxicity: Assess cancer cell killing and minimize effects on normal cells.
Stability and Distribution: Examine stability and distribution in a simulated environment.
In Vivo Evaluation
Experiment Design: Test efficacy and safety in animal models, focusing on drug metabolism and tumor clearance.
Dose Optimization: Identify optimal therapeutic doses and evaluate effects on tumors and normal tissue.
Alfa Cytology boasts robust R&D capabilities, with a specialized focus on 177Lu radiopharmaceutical development services. Our research team is equipped to handle a wide range of complex challenges. If you encounter any difficulties in your project, please don't hesitate to contact us. We are dedicated to offering comprehensive and professional support and assistance to ensure the success of your endeavors.
Reference
- HENNRICH U, EDER M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer [J]. Pharmaceuticals (Basel, Switzerland), 2022, 15(10).
For research use only. Not intended for any clinical use.
Related Service
